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Introduction
1-1  What are iPS Cells? 
    Our bodies are composed of cells differentiated into 
each organ within the limited period after fertilization, 
and the process of differentiation was long believed to 
be irreversible. 
    The advancement of research in cell differentiation, 
however, revealed the existence of stem cells 
possessing multi-potency after body development with 
the discoveries of embryonic stem cells (ES cells) by 
culturing early embryo and mesenchymal stem cells, 
multipotent cells in our bodies. Since then, there have 
been extensive efforts to find and obtain these multi-
potent cells. 
   In August 2006, Professor Shinya Yamanaka of 
Kyoto University succeeded in generating cells 
with pluripotent differentiation potential in mice 
by inserting just four genes (Oct3/4, Klf4, Sox2, 
c-Myc) into their mature skin cells, and named them 
induced pluripotent stem cells (iPS cells).[1] This 
groundbreaking new fact, which differentiated mature 
cells possess pluripotency, overturned the traditional 
belief that differentiation after fertilization was a one-
way process and proved that it was rather a plastic 
phenomenon. The four genes required to induce 
pluripotency are called Yamanaka factors. In addition, 
on July 20, 2007, one year after the discovery of iPS 
cells in mice, Prof. Yamanaka and his colleagues 
reported and proved that iPS cells could be generated 
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with human cells.[2] This, in other words, means that “a 
large amount of differentiating cells with the identical 
genes of the patient” can be prepared whenever 
necessary. 
   Human iPS cells were produced by inserting the 
same four genes (Oct3/4, Klf4, Sox2, c-Myc) used 
for murine iPS cells. Their method was simple and 
required no special equipment or technique, and was 
thus highly versatile. In addition, Prof. Yamanaka 
reported that insertion of only three genes (Oct3/4. 
Klf4. Sox2) could achieve iPS cells[3] making the 
method safer without the use of carcinogenic c-Myc 
gene. Moreover, the initial method using retrovirus 
vectors[NOTE 1], a possible carcinogen, is now improved 
with the use of plasmid vectors[NOTE 2] with less 
carcinogenic risks.[4] Plasmid vectors, with their 
ability to insert genes without damaging the genes 
of the targeting cells, are believed to be safer than 
retrovirus. Recently, a group from Max Plank Institute 
for Molecular Biomedicine in Germany succeeded 
in producing murine iPS cells by inserting only one 
gene, Oct4, with some chemical agents[5].
1-2   Expectations for Science and Medicine
   The importance of the discovery of iPS cells, as 
mentioned above, is the demonstration that the ability 
to differentiate into various organs was not exclusive 
to fertilized oocytes, but differentiated cells could 
achieve pluripotency as well with gene insertion. 
This proved the novel concept that pluripotency 
in differentiated cells could be re-set to a similar 
level as fertilized oocytes of early embryo. In other 
[NOTE1]
Retrovirus vectors are used to carry the genes to be inserted into the target cells.
[NOTE2]
Plasmid vectors are non-viral cyclic DNA gene carriers for gene insertion.
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words, it changed the entire strategy from “searching 
for” pluripotent cells to “generating” them with the 
establishment of an innovative technique that have 
the convenience of being able to “prepare whenever 
necessary,” thus providing “pluripotent cells with 
individually conserved genetic character” at all times. 
   The expected benefits of iPS cells go beyond 
research to applications in medicine and drug 
development with their potential for generating 
appropriate cells whenever necessary. Expectations 
are high especially in (1) application in drug 
development where evaluation of the safety and 
efficacy of candidate compounds can be done with 
human cells and tissues differentiated from human 
iPS cells rather than traditionally used animal tissues 
or cells, (2) application in regenerative medicine for 
patients who need repair and regeneration of tissues or 
function disordered in a disease by regenerating and 
grafting tissues and organs generated from iPS cells 
derived from the patients’ own cells, (3) in preparation 
of establishing an iPS cell bank with a collection of 
various types of human iPS cells, ready to provide 
a wide range of patients at any time, and (4) for 
treatments of congenital and intractable diseases[ 6, 7].
Scientific Innovation Triggered 
by iPS Cells
2-1  Application for Drug Development
   The earliest practical application of iPS cells is 
expected to be in the field of pharmaceutical research 
for developing new drugs. 
   The best way to evaluate the safety and efficacy of 
most drug candidates is with humans, though this 
comes with many risks. In addition to the obvious risks, 
since access to human cells and human disease model 
cells has been widely limited, these evaluations have 
been conducted mostly with animal cells and animal 
disease models such as mice. There are many issues, 
however, with the evaluations using animal models, 
such as a long development period. In addition, 
there have been incidents of finding unforeseen side 
effects and altered efficacy after the drug had been 
on the market due to frequent interspecies differences 
between humans and the animal model, in toxicity 
and efficacy.
    With the discovery of iPS cells, drug efficacy can be 
evaluated with human disease models differentiated 
from iPS cells derived from patients with the target 
disease right from the start. In addition, this technique 
allows access to certain cell types that are impossible 
to obtain from actual humans, such as cerebral 
neurons and cardiac muscle cells, and use them in 
evaluation. The use of iPS cells is expected to speed 
up the drug development process as well as obtain 
more information about side effects due to highly 
accurate evaluation with human cells. 
   Research and development of a toxicity-evaluation 
tool using human cardiac muscle cells generated from 
iPS cells started in October 2008 as a commissioned 
project of the New Energy and Industrial Technology 
Development Organization (NEDO). This project 
aims to establish a technique to evaluate early 
cardiac toxicity using iPS cells, with their technology 
to measure the pulsation of cardiac muscle cells 
developed in the existing NEDO project [8]. Since 
human myocardial cells were difficult to obtain, drug 
evaluation had to be conducted with animal model 
cells such as mice. With the available technology 
to generate human myocardial cells from iPS cells, 
efficacy and side effects of candidate drugs can 
be evaluated directly, enabling the development of 
drugs with better efficacy and fewer side effects in 
the future. In addition, omission of evaluation with 
animal cells is expected to contribute to a shortened 
development period and reduction of development 
cost. 
    The National Institute of Biomedical Innovation has 
produced iPS cells from patients with various diseases 
and is planning to differentiate them into cells such as 
hepatic cells, which are required for the evaluation of 
the toxicity, and metabolism of candidate drugs. This 
project is aiming to establish a technology for drug 
development by preparing iPS cells and differentiated 
cells derived from iPS cells of different sexes, ages, 
cell types and genetic backgrounds. Subsequent 
contribution to the improvement of drug safety (due to 
detailed toxicity evaluation in screening) is expected.[9] 
    In the future, the application of this technology will 
go beyond general drug development, and enable a 
pre-administration check of drug efficacy and toxicity 
with the cells differentiated from iPS cells derived 
from the patients’ own cells, allowing optimization of 
the dosage and prevention of side effects by applying 
it for individual administration management and 
detailed individual treatment. 
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Figure 1 :  Conceptual Diagram of Augologous Celll Therapy
(Conceptual diagram showing autologous cell therapy using iPS cells)
Prepared by the STFC
2-2  Application for Regenerative Medicine 
and Cellular Medicine (Treatment with 
Autologous Cells)
   One of the biggest dreams with iPS cells is their 
application in regenerative medicine. This is due 
partly to their pluripotency. The difficulty of obtaining 
necessary cells for treatment has slowed down 
regenerative medicine as cell therapy. However, the 
discovery of iPS cells, cells possessing pluripotency 
made from skin cells, has shed hopes for abundant 
access to iPS cells for regenerative medicine and 
necessary cells and/or tissues differentiated from them 
for graft treatment (Figure 1). 
The discovery of iPS cells has also shed special 
attention to autologous cell treatment, a type of 
treatment using patients’ own cells. This means, skin 
cells taken from a patient will be turned into iPS cells 
to obtain necessary cells and tissues via differentiation 
and culturing in order to use them for the treatment 
of the patient him/herself, the provider of the cells. 
Since these cells come from the patient, they will not 
be labeled foreign when they are returned in the body, 
and thus pose no risk of immunological rejection. 
iPS cells are not ideal for emergency use since it takes 
more than a few weeks to generate them. However, 
in cases where disease onset can be predicted, new 
medical divisions such as “emergency responsive 
medicine” and “preventative medicine” may now be 
operable. For example, for patients with high risks 
of cardiac infarct, preparation of myocardiac cells 
differentiated from iPS cells generated from their cells 
is now possible before the infarct attack.  
   A research team at the University of Tokyo, led 
by Professor Hiromitsu Nakauchi, has succeeded 
in differentiating iPS cells generated from human 
skin cells into thrombocytes via megakaryocytes by 
adding growth factors and co-culturing with bone 
marrow cells. This knowledge enables the generation 
of blood-related cells, such as white blood cells and 
red blood cells, and the concept of blood transfusion 
will be changed greatly in the future. 
  I n  Ja nu a r y  20 0 9,  t he  Fo o d  a nd  D r u g s 
Administ rat ion (FDA) of the United States 
approved Geron Corporation, an American venture 
company, to conduct a clinical test to treat eight to 
10 patients with paraplegia[NOTE 3] with human ES 
cells[10]. This is the world’s first clinical test using 
human ES cells, and the United States is expected 
to take the lead in the field of iPS cell application 
as well. 
   iPS cells will be applied in regenerative medicine 
in the near future when the safety of iPS cells is 
verified and safe differentiated cells derived from 
iPS cells are established. 
2-3  Use of Cell Bank (Homologous Cell 
Treatment)
   Another approach for cell therapy using iPS cells 
is to make them more general by building cell banks. 
This is not only for autologous cell therapy where iPS 
cells are used only for the provider of the cells but 
also for cell therapy for all patients, which is termed 
homologous cell therapy (human to human, using 
another person’s cells). 
An example showing a method to use autologous cells
Patient 
(i.e., Hepatitis)
Somatic Cell (i.e., Skin cell)
Insertion of 3 to 4 genes
iPS cells
Differentiation
Hepatic cells for treatment
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  Hu m a n  c e l l s  h a ve  d i f f e r e n t  t y p e s  o f 
histocompatibility antigen (HLA) on the cell surface, 
and a mismatch in the antigen type is recognized as 
foreign and subsequently triggers immunological 
rejection and elimination. According to a calculation 
by Professor Norio Nakatuji and his colleagues of 
the Institute for Frontier Medical Sciences of Kyoto 
University, to eliminate a mismatch that causes the 
immunological rejection, preparation of 170 different 
types of iPS cells can be used for 80% of the Japanese 
population[11, 12]. This suggests a possible use of 
iPS cells produced by other people’s cells in graft 
treatment in regenerative medicine by preparing many 
different HLA type cells to minimize the risks of 
rejection. 
   Treatment using this type of cell bank has been 
proposed by Professor Hideyuki Okano of Keio 
University. For cell therapy in a life-or-death 
emergency, such as treatment of spinal damage where 
grafting of nerve cells is ideally conducted on the 9th 
day post injury, iPS cells of the patients cannot be 
prepared in time. Therefore, for cases like this, it is 
ideal to build a bank within a cell bank for iPS cells 
without immunological rejection as well as a nerve 
cell bank using iPS cells for the treatment for spinal 
cord injury.[13]
   One example of current progress was demonstrated 
by principal research associate Hajime Ogushi of the 
National Institute of Advanced Industrial Science and 
Technology, who has succeeded in producing iPS cells 
from mesenchymal stem cells contained in pulled 
wisdom teeth. Since wisdom teeth were traditionally 
discarded, they are regarded as a great candidate for 
the cellular source for building an iPS cell bank[14]. 
    Resources at the iPS cell bank and cell bank derived 
from iPS cells for treatments are now expanding from 
homologous to heterologous cell therapy, and they are 
expected to be applied for emergency treatment of 
frequent injuries.
2-4  Treatment of Congenital and Intractable 
Diseases
   iPS cells are expected to open up a new way for 
the treatment of congenital and intractable diseases 
presently with no radical cure. This involves 
generation of iPS cells from the cells of patients with 
congenital diseases or genetically intractable diseases, 
their differentiation following the repair of damaged 
genes at the DNA level, and grafting them back to 
the body to regenerate normally functioning tissues 
and/or organs. Alternatively, the treatment could be 
done by grafting normal healthy cells derived from 
iPS cells to the lesions of patients with intractable 
diseases. Hemophilia, congenital immunodeficiency 
and Parkinson’s disease are among the target diseases.
   Already, a research team at Harvard University in the 
United States has reported that they produced iPS cells 
using skin or bone marrow cells of patients with 10 
different diseases, such as dystrophy, Down syndrome, 
diabetes and Parkinson’s disease.[15, 16] Another research 
team at Harvard reported a successful generation 
of iPS cells from elderly patients with amyotrophic 
lateral sclerosis (ALS) for the same purpose[17]. The 
United States seems to be leading the application of 
iPS cells by far at the moment. 
   In our country, collaboration between Kyoto 
University and Keio University has lead to a report at 
a Keio University symposium on February 4, 2009, 
that the grafting of nerve cells differentiated from 
human iPS cells into mice with spinal injuries on 
the ninth day post injury has resulted in significant 
recovery of motor ability compared to mice receiving 
no treatment post injury. This, though a preliminary 
experiment using mice, is the first case to show the 
efficacy of iPS cells in an animal disease model. 
   At Osaka University, in collaboration with 
Kyoto University and Tokyo Women’s Medical 
University, a myocardiac sheet was constructed 
with myocardiac cells differentiated from iPS 
cells derived from mouse fibroblast. When this 
myocardiac sheet was grafted in the infarct region of 
a cardiac infarct model created by ligation of the left 
anterior descending artery in mice, improvement 
in cardiac dysfunction and the suppression of a left 
ventricle enlargement was found.[18]
2-5   Repairing Organs
   Yet another new challenge has started to re-construct 
normally functioning organs and tissues by producing 
iPS cells from patients with acquired dysfunction in 
some parts of the body and by re-differentiating them 
inside the patient’s body. 
   Professor Nakauchi at the Institute of Medical 
Science of Tokyo University has cultured fertilized 
[NOTE3]
Paralysis in both legs below the waist
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oocytes, taken from mice with a deficit of genes to 
form a pancreas, to blastocyst and then injected iPS 
cells produced from normal mice. These blastocysts 
were subsequently implanted in a surrogate mother, 
and the resulting offspring formed pancreases with 
normal functions. Similarly, they have succeeded in 
forming kidneys, and the generation of these organs 
with bigger animals, such as pigs, is expected[19]. 
If this method proves to be successful in pigs, 
kidney transplants for patients with severe kidney 
dysfunctions are no longer just a pipedream since 
kidneys can be produced from differentiated iPS cells 
derived from the patient and by injecting them into pig 
blastocysts.
Research System
3-1  National Research Collaboration 
System
   As mentioned above, iPS cells are expected to be a 
source for drug development research as well as tools 
for frontier treatment for diseases. In addition, since 
this was discovered first by Prof. Yamanaka of Kyoto 
University, an “All Japan System” for research is now 
being constructed in order to lead in basic research 
and their use in the industry (Figure 2). 
   For the “Project to Achieve Regenerative 
Medicine,” four organizations, Kyoto University 
(Representative: Prof. Shinya Yamanaka), Keio 
University (Representative: Prof. Hideyuki Okano), 
University of Tokyo (Representative: Prof. Hiromitsu 
Nakauchi) and RIKEN (Representative: Dr. Yoshiki 
Sasai, Group Director), were chosen to strengthen 
the research using human iPS cells. With these four 
core institutions, they formed a network devoted for 
iPS cell research using human iPS cells, with each 
institution progressing in the research responsibly 
(Table 1).
    As a core institution to progress iPS cell research 
in our country along with the four core organizations, 
the Center for iPS Cell Research and Application 
(CiRA: Research Supervisor: Prof. Shinya Yamanaka) 
was founded at Kyoto University in January 2008. 
CiRA is in charge of developing a safe and efficient 
technique to produce iPS cells, developing growth 
control technology, establishing safety for clinical 
application and developing necessary technology for 
the application. In details, it sets eight goals, shown 
Promotional System for iPS Cell Research by the Ministry of Education, Culture, Sports, 
Science and Technology, aiming for the Construction of an All-Japan System
Stem Cell/Regenerative Medicine Strategy Committee, MEXT
(Member construct including program directors of practical application of a regenerative 




Research center for the 
development of treatment 
a n d  d i f f e r e n t i a t i o n 
induction using iPS cells
• Development of the technology to generate safe and 
effective iPS cells, technique to control proliferation and 
to evaluate and establish safety for clinical application.
RIKEN (Representative: 
Sasai GD)
Research Center for 
Differentiation Induction 
using iPS Cells
• Development of basic technique for efficient 
culturing of pluripotent stem cells such as 
iPS cells.
• Develop treatment and technology to induce 
differentiation focusing on the generation of 
sensory organs, and establish safety.
Kyoto University iPS Cell 
Research Center (Research 
Director: Prof. Yamanaka)
Practical application of regenerative medicine project
• Research regenerative medicine using iPS cells
• Progress of the entire program is managed by the 
program director and program office (Foundation for 
Biomedical Research and Innovation)
[MEXT iPS Cell Research Network (tentative title)]
Integrative application based on common rules (research 
network bylaw (tentative title)) will be in effect regarding 
distribution of iPS cells, intellectual property and 
research achievement
Core research organization 
for iPS cells
Establishment of iPS cells and improvement 
of culturing methods
(Organization in charge: RKEN Bioresource Center)
Keio Universi t y 
(Representative: 
Prof. Okano)
Research Center for 
treatment development 
a n d  d i f f e r e n t i a t i o n 
induction using iPS cells
• Develop treatment and differentiation induction 
technique for cells in the central nervous system, 
and establish safety.
University of Tokyo 
(R e p r e s e n t a t i ve: 
Prof. Nakauchi)
Research c ent e r  fo r 
treatment development 
a n d  d i f f e r e n t i a t i o n 
induction using iPS cells
• Develop treatment and differentiation induction 
technique focusing on the generation of vascular 
cells, and establish safety.
JST Basic Research Programs, “ Program Stem Cell 
Research Strategy Project using Cellular Reprogramming 
of iPS Cells”
• Investigate the mechanism related to the generation 
of iPS cells and upgrade the technique
• Research supervisor and program of f ice (JST) 
manage the entire project
Provided by reference[20]
Figure 2 : Promotional System for iPS Cell Research by the Ministry of Education, Culture, Sports, Science 
and Technology, aiming for the Construction of an All-Japan System
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Table 1 :  Four Research Centers Chosen as Human iPS Cells Research Centers and Abstracts of their Research
in Table 1, and takes charge of basic research to 
reveal the essence of iPS cells and to develop a safe 
differentiation induction technique.
   Keio University is the research center for practical 
application of iPS cells in regenerative medicine. 
They are in charge of applying their knowledge and 
expertise from their prior research of practical use 
of stem cells with ES cells and somatic stem cells 
before the discovery of iPS cells. In addition, in order 
to use iPS cells for the diseases shown in Table 1, 
they are aiming to achieve regenerative medicine by 
driving forward pre-clinical research, including tests 
with a primate model and confirmation of its safety. 
They focus on the development of a differentiation 
technique (especially in the central nervous system), 
confirmation of safety and research for treatment 
development. In addition, they have their eye on 
constructing iPS cell bank with many HLA type 
human iPS cells (goal: 200 strains) to target diseases 
in the central nervous system, hematopoietic system, 
cardiovascular system, and sensory system. 
   At the University of Tokyo, lead by the Stem Cell 
Treatment Research Center at the Institute of Medical 
Science Research, development of differentiation 
induction, safety confirmation and treatment 
development technology research will be undertaken. 
In addition, they will investigate specific diseases 
shown in Table 1. 
   At RIKEN, the development of basic technology 
for efficient culturing of iPS cells, the development 
Title
Title Representative Researcher Abstract
Integrative Research Center for iPS Cell Research at Kyoto University
Kyoto University Shinya Yamanaka
  In order to advance human iPS cells research correctly and quickly from its initial stage for 
their use in regenerative medicine, we aim to contribute not only in Japan but around the world 
by collaborating with rich resources of researchers at the Institute for Frontier Medical Sciences, 
Kyoto University Hospital and the Institute for Integrated Cell-Material Sciences, as well as with 
organizations outside of Kyoto University, such as Osaka University, with CiRA as the core research 
center.
  Goal: 1) To reveal the basic essence of iPS cells, 2) to develop safe and effective methods to 
generate iPS cells, 3) to develop technology to control proliferation and differentiation induction of 
iPS cells, 4) to develop treatment technology using differentiated cells in disease-related projects, 
5) to establish safety and evaluation techniques for clinical application, 6) to build a system to 
manage and operate intellectual property related to iPS cell research, 7) to found a basis of medical 
ethics specialized for iPS cells, 8) to standardize an iPS cell-generation technique, and to tirelessly 
progress iPS cell research in Japan with effective collaboration with related organizations outside of 
school, active utilization of resources of researchers and by sharing information.
Research Center for Practical Application of iPS cells, ES cells and Somatic Stem cells in Regenerative Medicine
Keio University Hideyuki Okano
  We aim to deepen our basic knowledge of the mechanisms of autonomous replication, 
differentiation and epigenetic control and culturing techniques on human iPS cells, ES cells, and 
somatic stem cells. In order to achieve actual practice of regenerative medicine, we aim to progress 
internationally top-level clinical research with primate models, to verify safety and efficacy with 
the use of these iPS cells, with a special focus on diseases involving the central nervous system, 
hepatopoietic system, cardiovascular system and sensory system. In addition, build a firm basis of 
human iPS cell research by generating and self-processing many different HLA types of human iPS 
cells. 
Development of Next Generation Gene and Cell Therapy Using iPS Cells
University of Tokyo Hiromitsu Nakauchi
  With the Center for Stem Cell Therapy Research at the Institute of Medical Science Research, 
as the core research center, organize a collaborative research system with 4 departments—the 
Department of Medical Research, University of Tokyo Hospital, Institute of Molecular and Cellular 
Biosciences and the Graduate School of Arts and Sciences—we aim to advance research in 
preparation of preclinical tests. As well as establishing a system to generate high quality human 
iPS cells derived from patients with careful consideration of safety and ethics, we aim to develop 
a system to regenerate a variety of organs such as blood, blood vessels, bone. cartilage, skeletal 
system, cardiac muscles, liver, pancreas and nerves from iPS cells. In addition, we also aim to 
develop new methods of gene-repair treatments using the characteristics of iPS cells for diseases 
such as hemophilia and congenital immunological dysfunction as well as to educate resources of 
researchers in regenerative medicine. 
Total Center for Technological Development of Differentiation Induction/Grafting as well as Technological Support for Human Pluripotent Stem Cells
©RIKEN Yoshiki Sasai
  We conduct technological development for highly efficient differentiation induction of human ES 
cells and iPS cells into neuronal, sensory and blood cells. At the same time, we aim to develop a 
culturing technique to improve safety, and to establish the basic methods for purification of generated 
usable cells. In addition, through grafting research using animal models, analyze their function 
in vivo, and establish the basis for medical application such as in cell therapy. In particular, with 
the goal of a practical use of human iPS cells, conduct preclinical tests on medium-sized animals 
for grafting of retinal cells (pigment epithelial cells), and establish a technology that is clinically 
applicable for age-related muscular degeneration and pigmentary retinal degeneration
  Through the collaboration between the main research center (Center for Developmental Biology) 
and the secondary research center (Bioresource Center) as a support center, contribute to the 
development of technology, resources and infrastructure by providing lecturing and transferring 
techniques, building, banking and providing useful cell strain, and by adjusting protocol in order to 
apply human stem cells such as iPS cells in regenerative medicine research in Japan.
Prepared by the STFC based on Reference[21]
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of differentiation induction especially in sensory 
system as well as safety confirmation and treatment 
development will be undertaken. 
   Some universities and research organizations other 
than the four aforementioned organizations indicated 
in Table 1 have started research using iPS cells 
(Table 2). Most are researching with aims to develop 
treatment for congenital diseases and genetically 
intractable diseases.
3-2  International Research Collaboration
   International research collaboration is still in the 
initial stage of relationship-building. As I will address 
later, there seem to be many difficulties to overcome to 
build a friendly international collaborative relationship 
with the current vigorous international competition for 
the rights to the intellectual property. 
   Under this condition, CiRA has agreed to form a 
partnership with an American corporation, Novocell, 
Inc. in September 2008, to research the differentiation 
of iPS cells to pancreatic cells. Novocell, Inc. has had 
previous success in creating pancreatic cells using ES 
cells, and now they will take the challenge of making 
pancreatic cells from iPS cells. This is aiming at the 
development of a radical cure for diabetes, and will be 
a big step in this area, anticipating high demand.[25]
   In addition, CiRa has signed an agreement on 
research collaboration with the University of Toronto 
in Canada in October 2008. This was for exchanging 
information about the induction, maintenance and 
differentiation technique of iPS cells for studying 
pathological conditions and developing treatments for 
intractable diseases using disease-specific iPS cells 
created from the cells of the patients.[26] 
   The Japan Science and Technology Agency 
(JST) has concluded a collaborative agreement for 
stem cell research with the California Institute for 
Regenerative Medicine (CIRM) of the United States 
in November 2008. Based on the agreement, they will 
support various international collaborative research 
activities by hosting seminars and interaction among 
researchers and international symposiums. In addition, 
they are planning to improve the environment for 
research interactions through sharing and transmission 
of information about iPS cell research and by hosting 
a research retreat for young researchers in iPS cell 
research[27]. 
3-3  Importance of Strategy for Intellectual 
Property
   As I have mentioned, iPS cells are expected to be 
used in the development of drugs and novel medical 
treatments. However, due to this industrialization, iPS 
cells will be an intellectual property and whenever 
they are used directly or indirectly, there will be a 
charge to be paid to the holder of the patent. Since 
iPS cells and the associated technology were first 
discovered by Kyoto University, they are believed to 
have an advantage in many technological contents 
which are to be patented. However, with the rapid 
Research Organization Research Focus
Tohoku University Development of regenerative treatment using autologous cornea cells generated from iPS cells
Nagoya University Development of novel vascular regenerative treatment using vascular precursor cells derived from iPS cells
Nagoya City University Actualization of stem cell treatment for periventricular leukomalacia
Osaka University Treatment  o f  card iac  d isease such as myocard iac  hyper t rophy us ing myocardial cells generated from iPS cells
Kyushu University Development of a safe and highly efficient method to differentiate hematopoietic stem cells using human iPS and ES cells
Kumamoto University Development of the basis for differentiation control from iPS cells to pancreatic βcells and for regenerative medicine for diabetes
National Center of Neurology 
and Psychiatry Development of stem cell graft treatment for dystrophy
National Institute of Biomedical Innovation Build evaluation database on pharmaceutical efficacy and side effects using iPS cells
National Institute of Advanced Industrial 
Science and Technology
Development of grafting treatment using genetically modified mesenchymal stem 
cell for severe congenital metabolic bone disease
Table 2 :  Major iPS Cell Research Organizations Other than the Four Selected Organizations and the 
Focus of Their Research
Produced at Science & Technology Trends Research Center based on references[22-24]
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cycle of research reports from many countries, such as 
the United States, a significant number of patents will 
likely be applied by these research organizations and 
corporations. 
   Publicized patent information to date indicates 
the first patent application on murine iPS cell 
generation by Kyoto University was on December 13, 
2005 (Japanese Patent). Similarly, the international 
application date including human iPS cell generation 
methods (aforementioned Japanese application date 
is the priority date) was December 6. On the other 
hand, application dates from others include Wisconsin 
University in the United States on March 23, 2007, 
Massachusetts Institute of Technology’s Whitehead 
Institute for Biomedical Research on April 7, 2007, 
Harvard University on May 30, 2007, and Bayer 
AG of Germany on June 15, 2007. Thus based on 
the application date, Kyoto University holds an 
advantageous position over the other patent applicants. 
In fact, on September 12, 2008, the first patent on 
the iPS cell generation methods by Kyoto University 
was accepted in Japan.[28] What is approved as rights, 
whether this patent is approved in other countries, 
and the approval of patents applied afterwards all 
depend on the content of the right requisition of patent 
application as well as the way that patents are regarded 
in each country. Therefore, it is necessary to pay 
attention to the transition in order to confirm whether 
the rights on truly necessary contents are protected.
   Kyoto University has started their effort to 
control their intellectual property by first setting a 
specialized division, iPS cell research intellectual 
property support, in the Office of Society-Academia 
Collaboration for Innovation in April 2008, and 
subsequently in August 2008, Intellectual Property 
Office in the Research Strategy Division at CiRA.[29] 
   On the other hand, the Japan Pharmaceutical 
Manufacturers Association (JPMA) has proposed 
that it is necessary for there to be an all-Japan 
support system that includes the industrial arena’s 
knowledge about strategy in intellectual property 
for iPS cell-related research accomplishment, at 
public and private dialogue with the ministers from 
Ministry of Economy, Trade and Industry, Ministry of 
Education, Culture, Sports, Science and Technology 
and Ministry of Health, Labor and Welfare in April 
2008.[30, 31] However, at this time, consortium is 
yet to be achieved. JPMA has started their own 
action and founded an intellectual property support 
project in November 2008 with contributions from 
13 companies on the executive board as one-year 
support, by analyzing and advising on the strategy 
for intellectual property of iPS cell-related research 
results, with a special focus on rights acquisitions in 
the United States.[32~34]
   In June 2008, iPS Academia Japan was founded 
to manage patented intellectual property on an iPS 
cell-generation method by Kyoto University, and to 
approve the rights to conduct patent discovery for 
companies aiming to develop medical treatment 
and drugs using the method.[35] Their principle is to 
provide nonexclusive license for free to non-profit 
organizations, such as universities, and provide a 
nonexclusive license onerously to profit-making 
organizations. To date (February 2009), they have 
started negotiations with more than 10 companies.
Challenges in the Future
4-1  Standardization of iPS Cells
   As we are still at the stage of gaining basic 
knowledge regarding the iPS cell generation, the 
definition of iPS cells -what exactly are iPS cells-
is still vague. Standardization of iPS cells, criteria 
to define iPS cells, and technological development 
for standardization are urgently needed for practical 
application of iPS cells. In particular, clones with 
different differentiation abilities obtained in the 
process of generating iPS cells require basic 
verification, such as the difference between the clones 
(inter-clone variance) and the way to controlling 
the changes within one clone over culturing and 
successive subculture (intra-clone variance).
   In the future, iPS cells are expected to be used 
all over the world, and Japanese research teams 
are desired to take a lead role in their universal 
standardization.
4-2  Treatment of Human Diseases
    Development for treatment of diseases in humans is 
one of the major possibilities with the use of iPS cells. 
Therefore, we should focus on whether it is actually 
possible and if so how this can be achieved. Especially, 
efforts should be made to develop treatments for 
genetic diseases and intractable diseases without any 
existing treatment. In addition, their adaptation for 
regenerative medicine with high demands should 
be made immediately. As I stated in 2-5, the United 
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States seems to take the lead in this area using their 
resourceful achievement with stem cell research. 
   One of the greatest contributions of the iPS 
cell discovery to human kind is that it gives hope 
and expectations for treatment to intractable and 
congenital disease patients. Therefore, we need to 
select candidate diseases on which to focus, as well 
as organize teams of clinical doctors and develop 
researchers for each disease to tackle the target 
intractable and congenital diseases. 
4-3  Guideline for Clinical Application
   In order to achieve a successful application of iPS 
cells in regenerative medicine and disease treatment, 
we need to build a seamless flow from basic research 
to applied research. Currently, the guideline for 
clinical tests using human iPS cells[36] seems to be 
applicable for tests using iPS cells. However, it is 
important to construct a guideline specifically for iPS 
cells that actively guides a user through basic research 
to their application, following the evaluation of 1) 
efficacy (benefit) and 2) safety (risks) of iPS cells, 
to achieve appropriate and speedy application using 
the results obtained. Therefore, research institutions, 
directing ministries and the industry should interact 
with each other to hold detailed yet active discussions 
in order for each opinion to be reflected directly on the 
guideline. 
    The FDA in the United States has already permitted 
Geron Inc. to conduct a clinical test using ES cells. In 
addition, in March 2009, President Obama signed an 
Exclusive Order to lift restrictions on federally funded 
embryonic stem cell research. Since the knowledge 
obtained from ES cell research is applicable to iPS 
cells, clinical application of iPS cells in the United 
States is expected to accelerate in the future. 
   In Japan, the application of regenerative therapy to 
patients has lagged behind the Western countries in 
the past due to overly strict policy for regenerative 
medicine as well as delayed revision of science and 
technology policies as they advanced. We can only 
hope for a quick setting of the policy for the clinical 
application of iPS cells. If, however, the policy is 
too conservative, the development of Japanese iPS 
cell therapy will be limited. This may result in the 
American medical industry and their supporters, with 
liberal approval to polish their pioneering medical 
technology, to reap all of the reward alone. 
4-4   Strategy for Intellectual Property
   As I mentioned, practical application of iPS cells 
is expected to start with the application for drug 
development followed by use in cell therapy. In 
particular, their clinical application for the treatment of 
intractable diseases is expected to be initiated by the 
United States following their first clinical application 
of ES cells to be conducted only about 10 years after 
their initial basic research. Considering the size of 
the market and the speed of practical application, it is 
important to get the patent in the United States as well 
as in Japan. 
   The method of generating iPS cells has been 
patented in Japan now. However, patenting of iPS 
cells themselves independent of their generation 
methods and of iPS cells and their differentiated cells 
derived from patients with intractable diseases is 
still the very basic aspect of the patents. In addition, 
although medical procedures could not be patented 
here, since they can be patented in the United States, 
a strategy to aim for an American patent is very 
important. For example, though both Europe and 
Japan have a “first come first served” policy on 
patenting, meaning the first submitted application is 
accepted even when the difference is only by a day 
or the content be identical, since the United States 
has “first to invent first served” policy, the date of the 
invention/discovery is critical and experiment notes 
act as important evidence. Therefore, the management 
of experiment notes of all researchers researching 
iPS cells is the basis for getting an American patent. 
At the “Life Science Intellectual Property Forum” on 
January 28, 2009, co-hosted by JPMA and the Japan 
Bioindustry Association, revision of the application 
method was discussed to include the American caveat 
policy to act on the ever so rigorous iPS cell-related 
research field with a shortening interval between new 
patent applications and presentations at academic 
conferences. 
   As shown here, considering the importance of 
the American patent of Intellectual Property, it is 
necessary to cooperate with those in the private 
sector who have extensive experience in obtaining 
American and international patents. In addition, patent 
application should be submitted as soon as a discovery 
is made in research, and in that sense, research and 
action for intellectual property rights need to be 
done simultaneously. Therefore, I emphasize the 
importance of the aforementioned system by JPMA, 
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    Presently, building a systemic strategy for obtaining 
intellectual property rights is the most urgent issue to 
overcome, with new research results coming everyday. 
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